High materiality8/10
H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
Why it may matterVerify against the original reporting
Bullish setup supported by continued Buy rating and a large upside target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
H.C. Wainwright reiterates Buy on Ascendis Pharma; target $344 vs current price of $260.81; priceChangeSinceSignal 0.16.
- Wainwright reiterates Buy; target $344 vs price $260.81.
Key facts
- 01
Target: $344
- 02
Posted price: $260.81
- 03
Analyst firm: H.C. Wainwright
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.